Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance

(2017) Quan-Yu Zhang et al.   HEPATOLOGY

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates

(2017) Pi-Xiao Wang et al.   NATURE MEDICINE

Update on the Mechanisms of Liver Regeneration

(2017) Morgan Preziosi et al.   SEMINARS IN LIVER DISEASE

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

(2017) Tisha R Joy et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

(2016) M. Nauck   DIABETES OBESITY & METABOLISM

Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System

(2016) Shivan J. Mehta et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis

(2016) Mei Xiang et al.   JOURNAL OF HEPATOLOGY

DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity

(2016) Lanfeng Xie et al.   JOURNAL OF HEPATOLOGY

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

(2016) Jeffrey Cui et al.   JOURNAL OF HEPATOLOGY

C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis

(2016) Khalidur Rahman et al.   LABORATORY INVESTIGATION

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice

(2016) Takaya Yamamoto   WORLD JOURNAL OF GASTROENTEROLOGY

IRE1α-TRAF2-ASK1 complex-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to CXC195-induced apoptosis in human bladder carcinoma T24 cells

(2015) Tao Zeng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial

(2015) Özlem Gögebakan et al.   DIABETOLOGIA

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

(2015) Stuart McPherson et al.   JOURNAL OF HEPATOLOGY

Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease

(2015) Sanjaya Satapathy et al.   SEMINARS IN LIVER DISEASE

Apoptosis signal-regulating kinase 1 as a therapeutic target

(2014) Yosuke Kawarazaki et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)

(2014) Yuichiro Eguchi et al.   HEPATOLOGY RESEARCH

Atmospheric gas plasma–induced ROS production activates TNF-ASK1 pathway for the induction of melanoma cancer cell apoptosis

(2014) Musarat Ishaq et al.   MOLECULAR BIOLOGY OF THE CELL

Inhibition of apoptosis signal-regulating kinase 1 enhances endochondral bone formation by increasing chondrocyte survival

(2014) G J Eaton et al.   Cell Death & Disease

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

(2014) Lise L Gluud et al.   BMJ Open

Potential of incretin-based therapies for non-alcoholic fatty liver disease

(2013) Susan L. Samson et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

(2013) Matthew J Armstrong et al.   BMJ Open

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program

(2012) M. J. Armstrong et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

ASK1 promotes apoptosis of normal and malignant plasma cells

(2012) F.-R. Lin et al.   BLOOD

Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice

(2012) Jinmi Lee et al.   PLoS One

Therapeutic targets in the ASK1-dependent stress signaling pathways

(2012) Ryoichi HAYAKAWA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice

(2011) Melissa A. Burmeister et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

(2011) Jamie E. Mells et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated mitogen-activated protein kinase

(2011) Hayato Nakagawa et al.   HEPATOLOGY

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

(2010) Michael A. Nauck   AMERICAN JOURNAL OF MEDICINE

Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours

(2010) D E White et al.   BRITISH JOURNAL OF CANCER

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

(2010) C. F. Deacon   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

Cellular FLICE-Inhibitory Protein Protects Against Cardiac Remodeling Induced by Angiotensin II in Mice

(2010) Hongliang Li et al.   HYPERTENSION

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

(2010) Shani Ben-Shlomo et al.   JOURNAL OF HEPATOLOGY

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis

(2009) Takayuki Iriyama et al.   EMBO JOURNAL

Apoptosis Signal-Regulating Kinase 1 Regulates Colitis and Colitis-Associated Tumorigenesis by the Innate Immune Responses

(2009) Yoku Hayakawa et al.   GASTROENTEROLOGY

c-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: Multiple roles in multiple steps

(2009) Yuzo Kodama et al.   HEPATOLOGY